IL-6 and IL-11 as markers for tumor aggressiveness and prognosis in gastric adenocarcinoma patients without mutations in Gp130 subunits

Journal of Gastrointestinal and Liver Diseases

Volumn 21, Issue 1, 2012, Pages 23-29

  Necula, Laura G ^a   Chivu Economescu, Mihaela ^a   Stanciulescu, Elena L ^b   Bleotu, Coralia ^a   Dima, Simona O ^c   Alexiu, Irina ^a   Dumitru, Adriana ^b   Constantinescu, Gabriel ^b   Popescu, Irinel ^c   Diaconu, Carmen C ^a  

^a STEFAN S NICOLAU INSTITUTE OF VIROLOGY   (Romania)

^b Floreasca Emergency Hospital   (Romania)

^c FUNDENI CLINICAL INSTITUTE   (Romania)

Author keywords

Gastric adenocarcinoma; Gp130; IL 11; IL 6; Progression

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 11; INTERLEUKIN 6;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA EXTRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POINT MUTATION; PROTEIN BLOOD LEVEL; SEQUENCE ANALYSIS; STOMACH ADENOCARCINOMA; STOMACH MUCOSA; SURVIVAL TIME; TISSUE LEVEL;

ADENOCARCINOMA; ADULT; AGED; CASE-CONTROL STUDIES; CYTOKINE RECEPTOR GP130; FEMALE; GASTRIC MUCOSA; GENETIC MARKERS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTERLEUKIN-11; INTERLEUKIN-6; MALE; MIDDLE AGED; POINT MUTATION; PROGNOSIS; SEQUENCE ANALYSIS, DNA; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84858854338     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Jackson CB, Giraud AS. STAT3 as a prognostic marker in human gastric cancer. J Gastroenterol Hepatol 2009; 24: 505-507.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Ahn HS, Lee HJ, Yoo MW, et al. Changes in clinicopathological features and survival after gastrectomy for gastric cancer over a 20-year period. Br J Surg 2011; 98: 255-260.
4. Economescu MC, Necula LG, Dragu D, et al. Identifcation of potential biomarkers for early and advanced gastric adenocarcinoma detection. Hepatogastroenterology 2010; 57: 1453-1464.
5. Grady WM, Tewari M. The next thing in prognostic molecular markers: microRNA signatures of cancer. Gut 2010; 59: 706-708.
6. Ernst M, Najdovska M, Grail D, et al. STAT3 and STAT1 mediate IL-11-dependent and infammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 2008; 118: 1727-1738.
7. Maekita T, Nakazawa K, Mihara M, et al. High levels of aberrant DNA methylation in helicobacter pylori infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006; 12: 989-995.
8. Handa O, Naito Y, Yoshikawa T. CagA protein of Helicobacter pylori: A hijacker of gastric epithelial cell signaling. Biochem Pharmacol 2007; 73: 1697-1702.
9. Tamura G. Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol 2006; 12: 192-198.
10. Gong W, Wang L, Yao JC, et al. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 2005; 11: 1386-1393.
11. Kanda N, Seno H, Konda Y, et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 2004; 23: 4921-4929.
12. Jenkins BJ, Grail D, Nheu T, et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med 2005; 11: 845-852.
13. Merchant JL. What lurks beneath: IL-11, via Stat3, promotes infammation-associated gastric tumorigenesis. J Clin Invest 2008; 118: 1628-1631.
14. Jarnicki A, Putoczki T, Ernst M. Stat3: linking infammation to epithelial cancer - more than a "gut" feeling? Cell Div 2010; 5: 14.
15. Nicholson SE, De Souza D, Fabri LJ, et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2- binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci U S A 2000; 97: 6493-6498.
16. Takahashi-Tezuka M, Yoshida Y, Fukada T, et al. Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase. Mol Cell Biol 1998; 18: 4109-4117.
17. Putoczki T, Ernst M. More than a sidekick: the IL-6 family cytokine IL-11 links infammation to cancer. J Leukoc Biol 2010; 88: 1109-1117.
18. Howlett M, Menheniott TR, Judd LM, Giraud AS. Cytokine signalling via gp130 in gastric cancer. Biochim Biophys Acta 2009; 1793: 1623-1633.
19. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
20. Contal C, O'Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Computational Statistics & Data Analysis 1999; 30: 253-270.
21. Yasui W, Sentani K, Motoshita J, Nakayama H. Molecular pathobiology of gastric cancer. Scand J Surg 2006; 95: 225-231.
22. Shang J, Peńa AS. Multidisciplinary approach to understand the pathogenesis of gastric cancer. World J Gastroenterol 2005; 11: 4131-4139.
23. Lehmann U, Schmitz J, Weissenbach M, et al. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem 2003; 278: 661-671.
24. Chen J, Huang XF. Interleukin-6 promotes carcinogenesis through multiple signal pathways. Comment on: Clinical signifcance of interleukin-6 gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci 2009; 54: 1373-1374.
25. Lin MT, Lin BR, Chang CC, et al. IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int J Cancer 2007; 120: 2600-2608.
26. Judd LM, Ulaganathan M, Howlett M, Giraud AS. Cytokine signalling by gp130 regulates gastric mucosal healing after ulceration and, indirectly, antral tumour progression. J Pathol 2009; 217: 552-562.